Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kristin Reiche

Showing results (51-60 of 72) with videos related to

Pageof 8
Sort By:
Cell Reports. Medicine|October 7, 2025
ROR2-specific CAR T cells are effective against hematologic and solid tumors and well tolerated in miceJustus Weber, Michael Rade, Josefine Michael, et al.
Nature Medicine|February 21, 2025
Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibodyTill Braun, Michael Rade, Maximilian Merz, et al.
Transplantation and Cellular Therapy|July 18, 2025
Prognostic Implications of Splenomegaly in BCMA-Directed CAR T-Cell Therapy for Relapsed MyelomaThomas C Wiemers, Maximilian Ferle, Jonas Ader, et al.
Hemasphere|December 10, 2025
Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and inferior outcome of CAR-T therapyLukas Scheller, Xiang Zhou, Henry Loeffler-Wirth, et al.
Frontiers in Immunology|June 21, 2021
Low Energy Electron Irradiation Is a Potent Alternative to Gamma Irradiation for the Inactivation of (CAR-)NK-92 Cells in ATMP ManufacturingLia Walcher, Ann-Kathrin Kistenmacher, Charline Sommer, et al.
Cancers|May 6, 2020
The Role of lncRNAs TAPIR-1 and -2 as Diagnostic Markers and Potential Therapeutic Targets in Prostate CancerMaik Friedrich, Karolin Wiedemann, Kristin Reiche, et al.
Genome Research|June 15, 2007
Structured RNAs in the ENCODE selected regions of the human genomeStefan Washietl, Jakob S Pedersen, Jan O Korbel, et al.
Journal of Immunotoxicology|December 10, 2024
Novel strategies to assess cytokine release mediated by chimeric antigen receptor T cells based on the adverse outcome pathway conceptMiriam Alb, Kristin Reiche, Michael Rade, et al.
Hemasphere|April 6, 2026
Body composition predicts poor outcomes and reveals immunometabolic dysfunction via single-cell profiling in anti-BCMA CAR T-treated myelomaThomas C Wiemers, Michael Rade, Nora Grieb, et al.
Blood Cancer Discovery|October 23, 2024
Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple MyelomaDavid Fandrei, Sabine Seiffert, Michael Rade, et al.
Pageof 8

Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
Cell Reports. Medicine|October 7, 2025
ROR2-specific CAR T cells are effective against hematologic and solid tumors and well tolerated in miceJustus Weber, Michael Rade, Josefine Michael, et al.
Nature Medicine|February 21, 2025
Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibodyTill Braun, Michael Rade, Maximilian Merz, et al.
Transplantation and Cellular Therapy|July 18, 2025
Prognostic Implications of Splenomegaly in BCMA-Directed CAR T-Cell Therapy for Relapsed MyelomaThomas C Wiemers, Maximilian Ferle, Jonas Ader, et al.
Hemasphere|December 10, 2025
Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and inferior outcome of CAR-T therapyLukas Scheller, Xiang Zhou, Henry Loeffler-Wirth, et al.
Frontiers in Immunology|June 21, 2021
Low Energy Electron Irradiation Is a Potent Alternative to Gamma Irradiation for the Inactivation of (CAR-)NK-92 Cells in ATMP ManufacturingLia Walcher, Ann-Kathrin Kistenmacher, Charline Sommer, et al.
Cancers|May 6, 2020
The Role of lncRNAs TAPIR-1 and -2 as Diagnostic Markers and Potential Therapeutic Targets in Prostate CancerMaik Friedrich, Karolin Wiedemann, Kristin Reiche, et al.
Genome Research|June 15, 2007
Structured RNAs in the ENCODE selected regions of the human genomeStefan Washietl, Jakob S Pedersen, Jan O Korbel, et al.
Journal of Immunotoxicology|December 10, 2024
Novel strategies to assess cytokine release mediated by chimeric antigen receptor T cells based on the adverse outcome pathway conceptMiriam Alb, Kristin Reiche, Michael Rade, et al.
Hemasphere|April 6, 2026
Body composition predicts poor outcomes and reveals immunometabolic dysfunction via single-cell profiling in anti-BCMA CAR T-treated myelomaThomas C Wiemers, Michael Rade, Nora Grieb, et al.
Blood Cancer Discovery|October 23, 2024
Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple MyelomaDavid Fandrei, Sabine Seiffert, Michael Rade, et al.
Pageof 8